Clinical Trial Update: Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the safety of Proellex (telapristone acetate) at 25 mg and 50 mg for symptomatic uterine fibroids; the study was terminated and results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Fibroids

Drugs mentioned

• Proellex (telapristone acetate)

Snippet

Sponsor: Repros Therapeutics Inc. | Conditions: Uterine Fibroids | Phase 3 | Status: TERMINATED | Results posted: 2014-08-21